AGP Picks View all

Michigan Technology Journal: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Michigan Technology Journal.

Press releases published on June 22, 2026

NVIDIA Announces Halos for Robotics, the Industry’s First Full-Stack Safety System for Physical AI
Europe Unveils a Record 35 New NVIDIA AI Supercomputers
INVO Fertility Reports First Quarter 2026 Results Reflecting Strong Revenue Growth, Expanded Fertility Clinic Platform, and Improved Capital Structure
NOVARC LAUNCHES NovAI AUTONOMY AS PART OF NovAI SUITE AND EXPANDS INTEGRATION TO YASKAWA AND ABB ROBOTS
SINTX Technologies Announces Receipt of More Than $3.2 Million in Contract Manufacturing Purchase Orders
Introducing Agent Architect and Agent Performance Suite for Zoom Virtual Agent
Cycode Named as a Leader in the 2026 Gartner® Magic Quadrant™ for Software Supply Chain Security
Inspired Entertainment Launches NBA Re-Play Virtual Sports in Turkey
Parexel Launches Parexel Biotech Incubator to Connect Early-Stage Innovation with Clinical Development Expertise
SPARC AI Registered as AUKUS Authorised User, Opening Pathway to US and UK Defence Markets
AIM ImmunoTech to Present in the Webull Corporate Connect Webinar Series
Enlivex Treasury Portfolio Update: RAIN Holdings Valued at Approximately $1.14 Billion
Achieve Life Sciences Receives Complete Response Letter from FDA for Cytisinicline NDA
SEALSQ’s QS7001 Post-Quantum Secure Element Aligned with New ANSSI Post Quantum Mandate
Next-Generation DNA Repair Therapies Open New Frontiers in Oncology
Novel Patented Myelin Drug-Discovery Strategy Targets Massive Unmet Need in Multiple Sclerosis
Entera Bio Receives Positive FDA Feedback on 12-Month Registrational Phase 3 Study for EB613 - the First Oral Anabolic Tablet in Development for Postmenopausal Women with Osteoporosis
NewGen Issues 3,666,667 New Shares in Connection with Strategic K25.ai Acquisition, Reaches Milestone of US$7.6 Million Market Capitalization
Clearmind Medicine Reaches Major Milestone, Completing Part A Treatment in FDA‑Regulated Phase I/II Trial
Verrica Pharmaceuticals Announces First U.S. Patient Dosed in the Second Pivotal Clinical Trial (COVE-3) of its Phase 3 Program Evaluating YCANTH® (VP-102) for the Treatment of Common Warts 

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

Michigan Technology Journal

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.